Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets
Latest news on ROCHE HOLDING LTD.
09:37a IONIS PHARMACEUTICALS : Pharma licenses -HTT Rx to Roche following successful ph..
12/13 ROCHE : Phase III IMmotion151 Study Showed Genentech's Tecentriq and Avastin Red..
12/13 IONIS PHARMACEUTICALS : Licenses IONIS-HTT Rx to Partner Following Successful Ph..
12/13 CHUGAI PHARMACEUTICAL : 'Atezolizumab' plus 'Avastin' Significantly Improves Pro..
12/13 IONIS PHARMACEUTICALS : scores huge breakthrough in Huntingtons, Roche licenses ..
12/13 ROCHE : Genentech researchers uncover epigenetic regulator of pancreatic cancer ..
12/13 ABBVIE : Roche boast stellar PhIII leukemia data for a breakthrough combo with b..
12/13 ROCHE : Researchers identify epigenetic orchestrator of pancreatic cancer cells
12/12 ROCHE : Join a Webinar with the Director of Corporate Credit at Roche Diagnostic..
12/12 ROCHE : Genentech's Hemlibra Continued to Substantially Reduce Bleeds in People ..
12/12 ROCHE : Phase II data showed Roche's investigational polatuzumab vedotin plus be..
12/12 ROCHE : Phase II Data Showed Genentech's Investigational Polatuzumab Vedotin Plu..
12/12 ROCHE : announces phase III data showing Venclexta/Venclyxto plus MabThera/Ritux..
12/12 GENENTECH : Announces Phase III Data Showing Venclexta Plus Rituxan Reduced the ..
12/12 ROCHE : Acquisition of Roche reagents and consumables
12/12 IONIS PHARMACEUTICALS : Roche To Licence Ionis Huntington`s Treatment After Tria..
12/12 MERCK AND : raises stakes in lung cancer treatments as rivals start to close in
12/12 IONIS PHARMACEUTICALS : gets $45M after Huntington's drug passes early test
12/11 ROCHE : Histone modifier is implicated in epithelial-mesenchymal transition
12/11 CHUGAI PHARMACEUTICAL : Emicizumab Every Four Weeks Showed Positive Interim Resu..
12/11 ROCHE : Genentech's HEMLIBRA Every Four Weeks Controlled Bleeds in Phase III Stu..
12/11 ROCHE : Genentech - Phase III IMpower150 Study Showed Tecentriq and Avastin Plus..
12/11 Merck raises stakes in lung cancer as rivals close in
12/11 ROCHE : Phase III IMmotion151 study showed Roche's Tecentriq (atezolizumab) and ..
12/11 ROCHE : Phase II data showed Roche's investigational polatuzumab vedotin plus be..
12/11 ROCHE : Meeting access challenges with adaptive trial designs
12/11DJROCHE : Reports Positive Results From IMmotion151 Kidney Cancer Trial
12/11 ROCHE : Tecentriq cocktail slows kidney cancer progression
12/11 ROCHE : Phase III IMmotion151 study showed Roche’s Tecentriq (atezolizumab..
12/11 ROCHE : Phase III IMmotion151 Study Showed Genentech’s TECENTRIQ (Atezoliz..
12/11 GENENTECH : Polatuzumab Vedotin Plus Bendamustine And Rituxan Increased CR Rates
12/10 ROCHE : Phase II data showed Roche’s investigational polatuzumab vedotin p..
12/10 ROCHE : Phase II Data Showed Genentech’s Investigational Polatuzumab Vedot..
12/09 ROCHE : Hemlibra continued to substantially reduce bleeds in people with haemoph..
12/09 GENENTECH : ’s HEMLIBRA (emicizumab-kxwh) Continued to Substantially Reduc..
12/09 DENI THERPAR : Denali IPO hits a 2017 record $1.7B market valuation, raising $25..
12/08DJROCHE : Novartis's Italian Heads Risk Trial for Alleged Market Rigging -Reuters
12/08 ROCHE : s haemophilia A drug shows meaningful bleed control in P3
12/08 ROCHE : Animal products, meat and meat products
12/07 ROCHE : ++ Roche, Novartis CEOs risk trial for scorning drug ++
12/07 Comeback in banks, tech lifts euro zone stocks as Steinhoff collapses
12/07 Roche drug cocktail doubles chance of holding lung cancer at bay
12/07 ROCHE : links with UK gov on digital pathology services
12/07 ROCHE : National Brain Tumor Society Statement on the Full Approval of Avastin
12/07 ROCHE : FDA Grants Genentech's Avastin Full Approval for Most Aggressive Form of..
12/07DJROCHE : Posts Positive Phase 3 Interim Results in Hemophilia Study
12/07DJROCHE : Reports Positive Results From IMpower150 Lung Cancer Trial
12/07DJROCHE : Immunotherapy Drug Tecentriq Extended Patients' Lives in Study
12/07 ROCHE : Hemlibra every four weeks controlled bleeds in phase III study in haemop..
12/07 ROCHE : Phase III IMpower150 Study Showed TECENTRIQ (Atezolizumab) and Avastin (..
12/07 GENENTECH : ’s HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Blee..
12/07 ROCHE : $25,410 Federal Contract Awarded to Roche Diagnostics
12/06 Roche to seize leap-frog opportunity in lung cancer
12/06DJROCHE : Avastin Granted Full Approval by FDA to Treat Glioblastoma
12/06 ROCHE : FDA grants Roche’s Avastin full approval for most aggressive form ..
12/06 FOUNDATION MEDICINE : FDA Approves First Multiplexed Companion Diagnostic for So..
12/06 REMINDER : Invitation to Roche’s live audio webcast and conference call po..
12/05 ROCHE : FDA Grants Genentech’s Avastin Full Approval for Most Aggressive F..
12/05 ROCHE : Genentech - First 'Cancer Screen Week' Calls on Americans to Act Now Aga..
12/05 ROCHE : Supports FDA Communication about Potential for Biotin Interference with ..
12/05 BIOCON : U.S. FDA Approves Mylan and Biocon's Ogivri, the First Biosimilar for T..
12/05 ROCHE : Genentech, American Cancer Society, Stand Up To Cancer, and Rally Health..
12/05 RECIPHARM PUBL : commences new supply contract and completes purchase of facilit..
12/05DJRoche's Breast Cancer Drug Herceptin Faces Biosimilar Competition -Cinco Dias
12/05 ROCHE : TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) FDA partial cl..
12/05 FOUNDATION MEDICINE : FDA approves test for cancer gene profiling
12/04 CHUGAI PHARMACEUTICAL : Organizational and Personnel Changes
12/04 FOUNDATION MEDICINE : FDA approves Foundation Medicine's FoundationOne CDx, the ..
12/04 FOUNDATION MEDICINE : Roche's Foundation Medicine wins FDA blessing for new canc..
12/04 ROCHE : FDA approves Foundation Medicine’s FoundationOne CDx, the first pa..
12/04 BIOCON : Mylan-biocon biosimilar drug gets usfda approval
12/02 ROCHE : Water mains
12/02 FOUNDATION MEDICINE : Strong Foundation
12/02 FOUNDATION MEDICINE : FDA OKs cancer gene test FDA approves first-of-a-kind test..
1  2  3  4  5  6  7  8  9  10Next
Financials ( CHF)
Sales 2017 53 500 M
EBIT 2017 18 164 M
Net income 2017 10 965 M
Debt 2017 10 098 M
Yield 2017 3,56%
P/E ratio 2017 18,18
P/E ratio 2018 16,67
EV / Sales 2017 4,07x
EV / Sales 2018 3,84x
Capitalization 208 B
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 274  CHF
Spread / Average Target 13%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.53%383 877
NOVARTIS12.01%221 304
PFIZER10.04%218 400
ROCHE HOLDING LTD.3.40%210 833
MERCK AND COMPANY-6.96%155 214